Skip to main content
Clinical Trials/CTRI/2023/03/051129
CTRI/2023/03/051129Not yet recruitingPhase 2

Comparative Evaluation of Advanced Platelet Rich Fibrin Plus and Enamel Matrix Derivative In The Treatment of Periodontal Intrabony Defects: A Randomized Clinical Trial

OT APPLICABLE0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Stage II or III Periodontitis.
  • Systemically healthy patient.
  • good level of oral hygiene with Full-Mouth Bleeding Score <20% and Full
  • Mouth Plaque Index Score <20%
  • presence of a minimum one or more 2-, 3-, or combined 2â??3-wall intrabony
  • defect with a defect angle of 20â??40 (±5) degrees
  • Pocket depths >= 6mm measured with UNC 15 probe.
  • Vertical bone loss >= 4mm seen on intraoral periapical radiograph.
  • No history of periodontal therapy in the preceding 6months.
  • No use of antibiotics in the preceding 6months which can interfere with bone healing.
  • Non-smokers

Exclusion Criteria

  • With known systemic illness such as Diabetes mellitus, arthritis and osteoporosis.
  • Patients on systemic medications such as corticosteroids or Calcium channel blockers or taking long-term NSAIDS or taking bisphosphonates
  • or calcium supplements.
  • Use of tobacco in any form and alcohol.
  • Teeth with Grade-III mobility and/or furcation involvement.
  • Immunocompromised individuals.
  • Pregnant or lactating females.
  • Tooth with hopeless prognosis.
  • Non-vital tooth with or without periapical pathology.
  • History of radiotherapy therapy in the preceding 1 year in head and neck region.

Investigators

Sponsor
OT APPLICABLE

Similar Trials